We were pleased to read the publication by Lan et al. 1 which included a meta‐analysis of the randomized controlled trials (RCTs) in which melatonin was used as a treatment for COVID‐19. Sixty‐two studies were considered, but only three RCTs (published before September 11, 2021) met the requirements for inclusion. 2 , 3 , 4 The primary outcome was the clinical recovery rate with secondary measures including the requirement for intensive care, level of inflammation, and mortality. The trial durations were 7–14 days with the total daily dose of melatonin being either 3, 6, or 9 mg. Eighty‐six patients were treated with melatonin and 85 received a placebo. Melatonin treatment significantly improved the recovery rate and provided evidence of a lowered requirement for intensive care, reduced mortality, and depressed inflammation (C‐reactive protein levels) compared to placebo. 2 , 3 , 4 The authors feel larger doses of melatonin maybe even more effective in combatting COVID‐19 infections.